The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Side effects and perceptions following Sinopharm COVID-19 vaccination
Open accessAbstract
Abstract Background Vaccines are one of the best interventions developed for eradicating COVID-19, the rapid creation of vaccinations was increased the risk of vaccine safety problems. The aim of this study to provide evidence on Sinopharm COVID-19 vaccine side effects which is approved by the United Arab Emirates (UAE). Methods A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of COVID-19 vaccine among individuals in the UAE. Demographic data, chronic conditions, side effects of the 1 st and 2 nd dose toward the vaccination, and the response of unwilling taking COVID-19 vaccine were reported. Results The most common side effects of post 1 st dose vaccination among participants (≤49 years old vs >49 years) were normal injection site pain 42.2%, fatigue 12.2%, and headache 9.6%, while pain at the vaccination site 32.6%, fatigue16.3%, lethargy13.7%, headache10%, and tenderness 10% were the most side effects of the post 2 nd dose of vaccination in both groups. All the side effects in both doses were more prevalent among the participants ≤ 49-year-old group. Among two groups (females vs males), the study revealed the increase in the number of females that suffered from the vaccine side effects compared with males in both doses. The most prevalence adverse reactions of first dose in (female’s vs males) were fatigue (15.8% vs 3.75%), lethargy (12.6% vs 1.25%), headache (10.5% vs 7.5%), while in 2 nd dose were fatigue (20% vs 7.5%), sever injection site pain (10.5% vs 2.5%). The most common reason of not willing to take the COVID-19 vaccine among the participants were the vaccines are not effective, and the participants were not authorized to take vaccine. Conclusion The 1 st and 2 nd dose post-vaccination side effects were mild, predictable, and there were no hospitalization cases, this data will help to reduce the vaccine hesitancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Interrater reliability: The kappa statistic
McHugh, M. L. (2012) · Biochemia Medica · doi:10.11613/bm.2012.031 · Cited by 19,877
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Similar to our results showed in various studies on COVID-19 vaccine side effects [16, 24, 28], Moreover, according to the Centers for Disease Control and Prevention (CDC), side effects tend to be more noticeable after the first dose [29].”
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00224-3 · Cited by 1,031
The Xs and Y of immune responses to viral vaccines
Klein, S. L., Jedlicka, A., & Pekosz, A. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70049-9 · Cited by 815
COVID-19 vaccines: where we stand and challenges ahead
on behalf of the COVID-19 Commission of Accademia Nazionale dei Lincei, R., Forni, G., & Mantovani, A. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00720-9 · Cited by 763
Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., et al. (2020) · JAMA · doi:10.1001/jama.2020.15543 · Cited by 759
Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
Sharma, O., Sultan, A. A., Ding, H., & Triggle, C. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585354 · Cited by 546
The how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 513
Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic
Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071428 · Cited by 395
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines
Chapin-Bardales, J., Gee, J., & Myers, T. (2021) · JAMA · doi:10.1001/jama.2021.5374 · Cited by 359
Kadali, R. A. K., Janagama, R., Peruru, S., & Malayala, S. V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.047 · Cited by 285
El-Shitany, N. A., Harakeh, S., Badr-Eldin, S. M., Bagher, A. M., Eid, B. G., Almukadi, H. S., Alghamdi, B. S., Alahmadi, A. A., Hassan, N. A., Sindi, N., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s310497 · Cited by 242
Resolution of coronavirus disease 2019 (COVID-19)
Habas, K., Nganwuchu, C., Shahzad, F., Gopalan, R., Haque, M., Rahman, S., Majumder, A. A., & Nasim, T. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1797487 · Cited by 231
Hatmal, M. M., Al-Hatamleh, M. A. I., Olaimat, A. N., Hatmal, M., Alhaj-Qasem, D. M., Olaimat, T. M., & Mohamud, R. (2021) · Vaccines · doi:10.3390/vaccines9060556 · Cited by 217
Akarsu, B., Canbay Özdemir, D., Ayhan Baser, D., Aksoy, H., Fidancı, İ., & Cankurtaran, M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13891 · Cited by 204
Kounis, N. G., Koniari, I., de Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S. F., Gogos, C., Kouni, S. N., Kounis, G. N., et al. (2021) · Vaccines · doi:10.3390/vaccines9030221 · Cited by 192
Riad, A., Sağıroğlu, D., Üstün, B., Pokorná, A., Klugarová, J., Attia, S., & Klugar, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122629 · Cited by 158
Sex-based Biology and the Rational Design of Influenza Vaccination Strategies
Klein, S. L., & Pekosz, A. S. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu066 · Cited by 144
Global Prevalence and Drivers of Dental Students’ COVID-19 Vaccine Hesitancy
Riad, A., Abdulqader, H., Morgado, M., Domnori, S., Koščík, M., Mendes, J. J., Klugar, M., Kateeb, E. T., & IADS-SCORE, O. B. O. (2021) · Vaccines · doi:10.3390/vaccines9060566 · Cited by 131
Survey of symptoms following COVID-19 vaccination in IndiaPreprint
Jayadevan, R., Shenoy, R., & Anithadevi, T. S. (2021) · medRxiv · doi:10.1101/2021.02.08.21251366 · Cited by 98
COVID-19 Vaccine: Critical Questions with Complicated Answers
Haidere, M. F., Ratan, Z. A., Nowroz, S., Zaman, S. B., Jung, Y.-J., Hosseinzadeh, H., & Cho, J. Y. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.178 · Cited by 80
Arab nations first to approve Chinese COVID vaccine — despite lack of public data
Cyranoski, D. (2020) · Nature · doi:10.1038/d41586-020-03563-z · Cited by 29
A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy
Zahid, M. N., Moosa, M. S., Perna, S., & BUTTI, E. B. (2021) · Arab Journal of Basic and Applied Sciences · doi:10.1080/25765299.2021.1903144 · Cited by 25
Metadata
- Authors
- Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., & Adrees, A. O.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 111
- Pages
- 219-226
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W3191428937
- Cited by
- 278
- References
- 30
- FWCI
- 19.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.